NCT05405166

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2022-06-23Est. Completion: 2024-11-06

Enrollment target: 531 participants

Locations

Rocky Mountain Cancer Centers - Aurora- Site Number : 8400021, Aurora, Colorado, United States
Mayo Clinic in Florida- Site Number : 8400008, Jacksonville, Florida, United States
Boca Raton Clinical Research Associates- Site Number : 8400030, Plantation, Florida, United States
Hattiesburg Clinic- Site Number : 8400006, Hattiesburg, Mississippi, United States
Atlantic Health System- Site Number : 8400005, Morristown, New Jersey, United States
New York Oncology Hematology - Albany Cancer Center- Site Number : 8400017, Albany, New York, United States
Novant Health Neurology & Sleep- Site Number : 8400014, Charlotte, North Carolina, United States
Gabrail Cancer Center- Site Number : 8400027, Canton, Ohio, United States
Oncology Hematology Care - Fairfield- Site Number : 8400016, Fairfield, Ohio, United States
Spartanburg Regional Medical Center- Site Number : 8400002, Spartanburg, South Carolina, United States
University of Texas - Southwestern Medical Center- Site Number : 8400024, Dallas, Texas, United States
Texas Oncology - San Antonio Medical Center - Research Drive- Site Number : 8400020, San Antonio, Texas, United States

Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma

This phase I trial investigates the side effects and best dose of ²¹¹At-OKT10-B10 when given together with fludarabine, …

Seattle, United StatesCompleted Dec 31, 2028

Relapsed/Refractory Multiple Myeloma (RRMM)

This study is researching whether the use of tocilizumab before the first dose of linvoseltamab will decrease the risk o…

Los Angeles, United StatesEst. completion Oct 11, 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.